The Best Biotin Supplements for Stronger Hair and Nails, According to Experts
Biotin is essential for hair and nail growth, and that simple fact is likely why it’s become such a buzz-worthy beauty ...
pharmaphorum4d
Sage, Biogen's zuranolone looks approvable, but will it sell?
Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...
The Business Journals10d
Sage rejects Biogen’s buyout offer, but says it's open to deals
The proposed merger of the two Cambridge drugmakers is off, but Sage says it's open to "strategic alternatives" — including a sale. Sage Therapeutics Inc. is looking for a deal — but it’s ...
Prevention23d
11 Best Biotin-Rich Foods to Add to Your Diet, According to a Derm and Nutritionist
Biotin, also known as vitamin B7, is an essential vitamin that helps convert food into energy. The most efficient way to fill up on the micronutrient? Eating biotin-rich foods. You see, biotin is ...
Reuters27d
Biogen proposes to buy remaining stake in Sage in $442 million deal
Jan 10 (Reuters) - Drugmaker Biogen (BIIB.O), opens new tab will buy all outstanding shares of Sage Therapeutics (SAGE.O), opens new tab that it does not already own for $7.22 apiece, a filing ...
The Business Journals27d
Biogen offers to buy out Sage Therapeutics
After a 2024 marred by a series of trial failures, Sage Therapeutics Inc. has received an acquisition offer from longtime partner Biogen Inc. on the eve of the biggest biotech event of the year.
FiercePharma24d
Biogen, already a Sage partner and equity owner, offers to buy the rest of the neuro biotech
Biogen has offered to purchase Sage’s outstanding shares for $7.22 each, according to a securities filing from Friday. The proposal values Sage at around $442 million. A yearslong partner of ...
Reuters23d
Biogen CEO sees no burning need for more acquisitions
SAN FRANCISCO Jan 14 (Reuters) - Biogen (BIIB.O), opens new tab expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business ...
Hosted on MSN23d
Biogen Wants to Buy Its Partner Sage for Almost No Premium
Shares of the biotech Sage Therapeutics were up nearly 40% on Monday after the company’s partner Biogen threw it a lifeline late Friday. Little has gone right for Sage in recent years ...
Yahoo Finance23d
Biogen bid for Sage does not change narrative, says BMO Capital
BMO Capital says Biogen (BIIB) is looking for an early potential deal by offering to buy Sage Therapeutics (SAGE) for $7.22 per share. Such an offer reflects Biogen’s interest in reducing its ...
Benzinga.com24d
1SAGE, BIIB : Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy:...
Biogen offers $7.22 per share to acquire Sage Therapeutics. Goldman Sachs projects Zurzuvae could reach $700 million in global sales by 2034. Get Pro-Level Earnings Insights Before the Market ...